Dongcheng Pharmaceuticals (002675.SZ): Clinical trials of 177Lu-LNC1009 injection have been approved, and currently there are no similar products on the market both domestically and internationally.

Wisdom Financial APP news, Dongcheng Pharmaceutical (002675.SZ) announced that on December 5, 2025, its controlling subsidiary Yantai Lanna Cheng Biological Technology Co., Ltd. (hereinafter referred to as "Lanna Cheng") received the drug clinical trial approval notice for 177Lu-LNC1009 injection issued by the China National Medical Products Administration (hereinafter referred to as "NMPA"), and will soon begin clinical trials.